A prospective audit on the use of prophylactic antiemetics and rates of CINV in patients receiving carboplatin AUC ≥4 or combination anthracycline-cyclophosphamide

CONCLUSION: The rates of CINV are high with the existing antiemetic regimens used at MidCentral Regional Cancer Treatment Service. Therefore, in accordance with international guidelines, we will add a neurokinin-1 antagonist to the antiemetic regimens for patients receiving carboplatin-based chemotherapy AUC≥4, and olanzapine for those receiving combination anthracycline/cyclophosphamide chemotherapy, in an attempt to improve the rates of CINV in these groups. Repeating this audit post-implementation of above recommendations will be important to assess for any improvement.PMID:33927422

Source: New Zealand Medical Journal - April 30, 2021 Category: General Medicine Authors: Edward Lo Malcolm Anderson Rebecca Carroll Garry Forgeson Richard Isaacs Jody Jordan Liyana Satterthwaite Navin Wewala Jennifer Fernando Source Type: research